Molecular Imaging in Neurodegenerative Disorders: Developing a Translational Toolbox

Presenter: Ken Marek, M.D. | Distinguished Scientist, Invicro

Molecular imaging has emerged as a key tool to advance our understanding of the pathobiology, and accelerate the development of therapeutics for Alzheimer's Disease (AD), Parkinson's Disease (PD) and other neurodegenerative disorders. Imaging has been widely utilized to identify disease pathology and enrich clinical studies, monitor disease progression and assess the effect of therapeutics on disease.  

The development of highly sensitive and selective imaging tools coupled with the standardization of collection and analysis of imaging data has revolutionized clinical neurology studies. Within the biomarker consortium, including the Alzheimer's Disease neuroimaging initiative and Parkinson's progression marker initiative, imaging provides a benchmark to establish other biomarkers and better categorize disease pathology.              

During this webinar, the presenter will:

  1. Discuss the current molecular imaging landscape for Alzheimer's Disease and Parkinson's Disease
  2. Review the utility of molecular imaging across the continuum of neurodegenerative disease from preclinical to disease diagnosis to manifest illness
  3. Examine the potential for molecular imaging to assist in the development of novel therapeutics for neurodegenerative disorders
Friday, October 16
8:00am EDT

Register for On-Demand Access:

KenMarek-1-1

Ken Marek, M.D.

Distinguished Scientist, Invicro

Dr. Marek is a neurologist with widespread expertise in neurodegenerative disorders. He is internationally recognized as an expert in imaging of neurodegenerative disorders and has made significant contributions to early detection and diagnostic use of radiotracers, particularly for Parkinson's Disease, Alzheimer's Disease, Huntington's Disease (HD) and other disorders. Dr. Marek has developed novel clinical design for brain imaging studies and has been the Principal Investigator in several multicenter trials, including PPMI and PARS.